额外静脉注射Ustekinumab的再诱导是耐火克罗恩病患者的有效优化策略
Jiayin Yao1,2, Xiang Peng1,2, Yingkui Zhong1,2
1Department of Gastroenterology, The Sixth Affiliated Hospital, Sun Yat-Sen University, Guangzhou, Guangdong Province, China.
对于耐火性克罗恩病,静脉注射乌斯特基努马布 (UST) 的再诱导比缩短恢复临床和内镜缓解的间隔更有效. 在考虑替代生物疗法之前,应该优先考虑这种策略.
科学领域:
- 胃肠病学 胃肠病学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 乌斯特基努马布 (UST) 是克罗恩病 (CD) 的一种生物疗法.
- 优化策略,如间隔缩短或再诱导用于部分或损失的响应.
- 对这些UST优化策略的比较证据有限.
研究的目的:
- 评估基于体重的UST静脉再诱导的疗效和安全性.
- 为了比较耐火性CD患者的静脉再诱导与间隔缩短.
主要方法:
- 对128名耐火性CD患者进行了回顾性观察性研究.
- 患者接受了UST间隔缩短 (q8w/q4w) 或静脉注射再诱导,然后进行皮下UST.
- 评估了临床 (CDAI),生化 (CRP) 和内镜 (SES-CD) 反应,UST最低度和不良事件.
主要成果:
- 与间隔缩短相比,静脉注射再诱导显示了CDAI的显著改善.
- 在静脉注射再诱导后,UST的最低度显著增加.
- 静脉注射再诱导组的临床 (69.6%) 和内镜 (31.8%) 缓解率高于缩短间隔组 (62.9%和22.2%).
- 两组之间没有发现显著的安全差异.
结论:
- 静脉输入性UST再诱导是恢复耐火性CD的临床和内镜缓解的有效策略.
- 优先考虑静脉注射再诱导,而不是简单地缩短UST间隔.
- 在转向针对不同途径的生物药物之前,请考虑缩短间隔.
更多相关视频
07:45Ultrasound-guided Intracardiac Injection of Human Mesenchymal Stem Cells to Increase Homing to the Intestine for Use in Murine Models of Experimental Inflammatory Bowel Diseases
Published on: September 1, 2017
08:02In Vivo Augmentation of Gut-Homing Regulatory T Cell Induction
Published on: January 22, 2020
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Drugs for Treatment of Ulcerative Colitis in IBD
Inflammatory Bowel Disease II: Crohn's Disease
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
